2024-07-25T16:20:47-05:00 2023-09-30 953309779 GURSEY SCHNEIDER LLP 2121 AVENUE OF THE STARS SUITE 1300 LOS ANGELES CA 90067 990 2022-10-01 954296919 INTERNATIONAL MYELOMA FOUNDATION INTE 8184877455 4400 COLDWATER CANYON AVE SUITE 3 STUDIO CITY CA 91604 YELAK BIRU PRESIDENT 8184877455 2024-07-10 1 YELAK BIRU 999009999 0 NAZ AFSHAR P00441843 3105520960 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z YELAK BIRU 4400 COLDWATER CANYON AVE SUITE 300 STUDIO CITY CA 91604 16752420 0 X WWW.MYELOMA.ORG X 1990 CA DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 20 19 50 0 0 0 17808047 16285176 6770 23217 247858 437293 0 0 18062675 16745686 212650 263667 0 0 7666529 7251420 0 0 1133659 8939853 10896030 16819032 18411117 1243643 -1665431 18463467 18245423 6761429 7727579 11702038 10517844 X DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 0 0 7307024 196667 RESEARCH - THE INTERNATIONAL MYELOMA FOUNDATION (IMF) IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. IMF SUPPORTS LAB-BASED RESEARCH AND HAS AWARDED OVER 151 GRANTS TO TOP JUNIOR AND SENIOR RESEARCH SCIENTISTS SINCE 1995. IN ADDITION, IMF BRINGS TOGETHER THE WORLD'S LEADING EXPERTS IN THE MOST SUCCESSFUL AND UNIQUE WAY THROUGH THE INTERNATIONAL MYELOMA WORKING GROUP, WHICH IS PUBLISHING IN PRESTIGIOUS MEDICAL JOURNALS, CHARTING THE COURSE TO A CURE, MENTORING THE NEXT GENERATION OF INNOVATIVE INVESTIGATORS, AND IMPROVING LIVES THROUGH BETTER CARE. THE BLACK SWAN RESEARCH INITIATIVE IS A MULTINATIONAL CONSORTIUM OF LEADING MYELOMA EXPERTS WHO ARE HARNESSING NEW TECHNOLOGIES AND THE LATEST MYELOMA TREATMENTS TO FIND A PATHWAY TO A CURE. THE BLACK SWAN RESEARCH STRATEGY CAPITALIZES ON THE AVAILABILITY OF POTENT NOVEL THERAPIES AND THE ADVENT OF ULTRA-SENSITIVE TESTS TO MEASURE EXACTLY WHEN AND HOW THOSE THERAPIES ARE WORKING IN PATIENTS. THE BLACK SWAN RESEARCH INITIATIVE IS DEDICATED TO DEVELOPING NEW CURATIVE THERAPIES FOR MYELOMA. 2940039 EDUCATION AND AWARENESS - ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN THEY FIRST HEARD THE WORD "MYELOMA". IMF RECOGNIZES THE NEED FOR COMPREHENSIVE EDUCATION PROGRAMS FOR BOTH THE PATIENT AND THE PHYSICIAN TO ENSURE THAT PATIENTS ARE DIAGNOSED CORRECTLY AND TREATED EFFECTIVELY. OUR LIBRARY OF MORE THAN 100 PUBLICATIONS FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, IS AVAILABLE FREE OF CHARGE. PUBLICATIONS ARE UPDATED ANNUALLY AND AVAILABLE IN MORE THAN 19 INTERNATIONAL LANGUAGES. THE IMF EMPOWERS PATIENTS AND THEIR CAREGIVERS TO JOIN HEALTHCARE PROVIDERS AS ACTIVE DECISION-MAKING PARTNERS, LEADING TO THE BEST POSSIBLE QUALITY OF LIFE FOR EACH INDIVIDUAL MYELOMA PATIENT. THE IMF PRODUCES COMPREHENSIVE BUT 'USER-FRIENDLY' INFORMATION FOR THE ENTIRE MYELOMA COMMUNITY. THE IMF'S PUBLICATIONS LIBRARY INCLUDES AN EXTENSIVE CATALOG OF BOOKLETS, TIP CARDS, ARTICLES, WEBINARS AND TELECONFERENCES, BLOGS, DIGITAL MEDIA AND INTERVIEWS, ALL WRITTEN, CREATED, AND PRODUCED BY THE IMF WITH OVERSIGHT BY ITS SCIENTIFIC ADVISORY COMMITTEE. THE IMF LIBRARY'S BROAD SCOPE INCLUDES INFORMATION ABOUT MYELOMA TREATMENT OPTIONS, CLINICAL TRIALS, DIVERSITY, EQUITY AND QUALITY OF LIFE CONSIDERATIONS FOR PATIENTS AND PHYSICIANS. 1461034 PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND ALLOW PARTICIPANTS TO SHARE THEIR PERSONAL EXPERIENCES AND SUPPORT. PREMIER MYELOMA EXPERTS VOLUNTEER THEIR TIME TO THE SEMINARS, TO EMPOWER PATIENTS AND THEIR FAMILIES TO MAKE EDUCATED TREATMENT CHOICES TAILORED TO THEIR NEEDS. IN ADDITION TO PATIENT AND FAMILY SEMINARS, THE IMF FACILITATES REGIONAL COMMUNITY WORKSHOPS, WHICH SERVE AS CONDENSED SEMINARS IN SMALLER CITIES TO EXPAND THE REACH OF IMF PROGRAMS AND UP-TO-DATE INFORMATION ON MYELOMA CARE, SUPPORT AND TREATMENT TO A WIDER AUDIENCE AT NO CHARGE. 4689328 67000 23217 INTERNATIONAL - THE IMF GROWS ITS NETWORK OF HEALTH CARE PROFESSIONALS AROUND THE WORLD. KEY TEAM MEMBERS ORGANIZE PHYSICIAN AS WELL AS PATIENT MEETINGS IN ORDER TO PROVIDE EDUCATION ABOUT THE LATEST DEVELOPMENTS IN THE FIELD OF MULTIPLE MYELOMA.SUPPORT GROUPS - THROUGH A GLOBAL COMMUNITY OF VOLUNTARY SUPPORT GROUPS, THE IMF SEEKS TO ENSURE THAT PATIENTS AND FAMILIES HAVE LOCAL ACCESS TO SUPPORT AND EDUCATION. THE IMF CURRENTLY SUPPORTS OVER 300 SUPPORT GROUPS WORLDWIDE. THE IMF OFFERS UNEQUALED WEBSITE CREATION AND HOSTING FOR LOCAL SUPPORT GROUPS, AND PROVIDED A UNIQUE OPPORTUNITY FOR SOME SUPPORT GROUP LEADERS TO ATTEND THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. THE 24TH ANNUAL SUPPORT GROUP LEADERS SUMMIT TOOK PLACE WITH MORE THAN 90 LEADERS IN ATTENDANCE. TECHNOLOGY CONTINUES TO BE EMPHASIZED FOR SUPPORT GROUP LEADERS. DURING THE PANDEMIC, THE IMF TRANSITIONED MORE THAN 100 SUPPORT GROUPS TO VIRTUAL MONTHLY MEETINGS, AND CONTINUES TO SUPPORT AND MAINTAIN THESE MONTHLY MEETINGS. THE IMF ALSO CONTINUED TO UPDATE ITS APP SPECIFICALLY DESIGNED FOR SUPPORT GROUP LEADERS WHICH OFFER MEETING AND EDUCATION MATERIALS ACCESSIBLE TO HELP BUILD EFFECTIVE COMMUNICANURSE - THE IMF NURSE LEADERSHIP BOARD IS A PROFESSIONAL PARTNERSHIP REPRESENTING NURSE EXPERTS CARING FOR MYELOMA PATIENTS AT LEADING MEDICAL CENTERS. FOUNDED IN NOVEMBER 2006, THE NLB HAS PROVEN TO BE INVALUABLE TO THE MYELOMA COMMUNITY AS A PLATFORM THAT BOLSTERS NURSING EDUCATION, CLINICAL CARE EXPERIENCE EXCHANGE, AND PATIENT KNOWLEDGE AND EMPOWERMENT IN AN EFFORT TO OPTIMIZE OUTCOMES FOR PATIENTS WITH MYELOMA. THIS BOARD OF EXPERIENCED MYELOMA NURSES HAS MADE GREAT STRIDES IN IMPROVING THE NURSING CARE AND SELF-CARE OF MYELOMA PATIENTS SINCE ITS INCEPTION.CLINICAL MEETINGS - IMF TEAM MEMBERS ORGANIZE CLINICAL MEETINGS, BRINGING TOGETHER THE WORLD'S LEADING MYELOMA EXPERTS, TO FORM A COALITION THAT WILL WORK COLLABORATIVELY ON MYELOMA-RELATED PROJECTS AND AVOID DUPLICATION OF EFFORTS AND DILUTION OF VALUABLE RESOURCES. THESE COALITIONS PROMOTE EXCELLENCE IN CLINICAL PRACTICE, RESEARCH AND EDUCATION AND CME-ACCREDITED MEDICAL EDUCATION PROGRAMS. THIS PAST YEAR ALSO INCLUDED EDUCATION TO THE COMMUNITY PHYSICIAN AND NURSE VIA ONLINE AND LIVE INSTRUCTION.ADVOCACY - THE IMF IS DEDICATED TO CREATING A GLOBAL COMMUNITY THAT SUPPORTS THE WIDE-RANGING NEEDS OF ALL AFFECTED BY MYELOMA. THE IMF ADVOCATES ON BEHALF OF THOSE AFFECTED BY MULTIPLE MYELOMA FOR AN INCREASE IN ACCESSIBILITY OF HIGH-QUALITY DIAGNOSTICS AND TREATMENTS, FOR FUNDING OF MYELOMA-RELATED RESEARCH, AND FOR AN END TO INSURANCE COVERAGE DISPARITIES FOR TREATMENT. THE IMF INCLUDES THE ENTIRE MYELOMA COMMUNITY IN THESE EFFORTS AND CONTINUES TO EXPAND ITS COMMITMENT TO EMPOWERING PATIENTS, FAMILIES, AND FRIENDS TO ADVOCATE ON BEHALF OF PATIENT RIGHTS.INFOLINE - THE IMF'S TOLL-FREE INFORMATION TELEPHONE LINE PROVIDES LIFE-SAVING AND LIFE-CHANGING MYELOMA TREATMENT AND MANAGEMENT SUPPORT FROM COMPASSIONATE, HIGHLY TRAINED SPECIALISTS. AS NEW TREATMENT OPTIONS ARE GAINING ATTENTION AND USE IN MULTIPLE MYELOMA, ANSWERING QUESTIONS ABOUT MYELOMA, ITS TREATMENT, DRUG SIDE EFFECTS, OPTIONS FOR POSSIBLE CLINICAL TRIALS OTHER HEALTH CONCERNS, AND WHERE TO FIND LOCAL SUPPORT IS MORE IMPORTANT THAN EVER.WEBSITE - THE IMF WEBSITE IS THE LEADING RESOURCE FOR MYELOMA-RELATED CONTENT AND THE MOST COMPLETE SOURCE OF ANSWERS FROM THE MANY QUESTIONS ASKED BY THOSE NEWLY DIAGNOSED TO THOSE MANAGING MYELOMA FOR MANY YEARS. THE WEBSITE CONSIDERS PATIENTS, CAREGIVERS, FAMILY MEMBERS, AND HEALTHCARE PROFESSIONALS. INFORMATION IS AVAILABLE IN MULTIPLE LANGUAGES AND FOCUS IS ON THE IMF'S RESEARCH, EDUCATION, SUPPORT AND ADVOCACY INITIATIVES.MYELOMA TODAY - MYELOMA TODAY IS A QUARTERLY NEWSLETTER AND THE GO-TO RESOURCE FOR THE MYELOMA COMMUNITY TO LEARN ABOUT THE LATEST ADVANCES IN MYELOMA TREATMENT, RESEARCH AND QUALITY OF LIFE ISSUES. IT IS PROVIDED FREE OF CHARGE.INFORMATIONAL MAILINGS - THE INFOPACK IS MADE UP OF A SELECTION OF THE IMF'S PUBLICATIONS AND IS DESIGNED TO PROVIDE NEWLY DIAGNOSED PATIENTS AND THEIR FAMILIES WITH A COMPLETE UNDERSTANDING OF THE DISEASE AND CARE. THE INFO PACK CONTAINS INFORMATIVE MATERIALS FREE OF CHARGE IN 19 LANGUAGES. 4689328 67000 23217 16397425 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 1 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 39 0 1 50 1 0 0 0 0 0 0 0 0 0 0 0 0 X 20 19 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC OH OK OR PA RI SC TN UT VA WA WV WI X X X JENNIFER SCARNE 8184877455 4400 COLDWATER CANYON AVE SUITE 300 STUDIO CITY CA 91604 YELAK BIRU CEO, PRESIDENT 40.00 X X 412083 0 17822 SUSAN DURIE DIRECTOR 40.00 X 256967 0 28716 DR BRIAN DURIE DIRECTOR 1.00 X 342333 0 358 JACK AIELLO DIRECTOR 1.00 X 0 0 0 CHRISTINE BATTISTINI DIRECTOR 1.00 X 0 0 0 DR MARIO BOCCADORO DIRECTOR 1.00 X 0 0 0 LORAINE BOYLE DIRECTOR 1.00 X 0 0 0 MARTINE ELIAS DIRECTOR 1.00 X 0 0 0 GEORGE T HAYUM DIRECTOR 1.00 X 0 0 0 JASON KATZ DIRECTOR 1.00 X 0 0 0 BENSON KLEIN DIRECTOR 1.00 X 0 0 0 ANDREW KUZNESKI III DIRECTOR 1.00 X 0 0 0 DR ROBERT A KYLE DIRECTOR 1.00 X 0 0 0 DR HEINZ LUDWIG DIRECTOR 1.00 X 0 0 0 DR EDITH MITCHELL DIRECTOR 1.00 X 0 0 0 CHARLES NEWMAN DIRECTOR 1.00 X 0 0 0 MATTHEW ROBINSON DIRECTOR 1.00 X 0 0 0 DR VINCENT RAJKUMAR DIRECTOR 1.00 X 0 0 0 E MICHAEL D SCOTT DIRECTOR 1.00 X 0 0 0 SANJAY SINGH DIRECTOR 1.00 X 0 0 0 JENNIFER SCARNE CHIEF FINANCIAL OFFICER 40.00 X 281385 0 20241 DIANE MORAN STRATEGIC PLANNER 40.00 X 409891 0 15369 LISA PAIK SENIOR VICE PRESIDENT 40.00 X 257083 0 23854 JOSEPH MIKHAEL CHIEF MEDICAL OFFICER 40.00 X 455869 0 16868 PETER ANTON VICE PRESIDNENT, MARKETING 40.00 X 204913 0 28760 LYNN GREEN SENIOR VICE PRESIDENT, PHI 40.00 X 228343 0 570 2848867 0 152558 23 0 1 0 MIMI CHOON-QUINONES IM CHRUZ 17 ARISDORF BASEL LAND SZ 4422 INTERNATIONAL ADVOCACY, ACCESS, POLICY, 230004 DAN NAVID SIRA SILA 20/46 SOI 97 HUA HIN TH 77110 INTERNATIONAL GLOBAL STRATEGY 208000 MICHELLE FABER 8605 LEXINGTON PLACE WEXFORD PA 15090 GRANT SUPPORT AND PROGRAM MANAGEMENT 106898 3 19741 16265435 16285176 SUPPORT GROUP 611710 23217 23217 23217 437293 437293 6734 19741 6734 0 16745686 23217 0 437293 120000 120000 143667 143667 996498 819961 86046 90491 6254922 5146815 540103 568004 280491 261241 11258 7992 63692 53178 6352 4162 1173200 1127993 7313 37894 434333 319962 95094 19277 343994 305283 23033 15678 158922 91563 39636 27723 716146 715535 611 2874604 2770504 30274 73826 90363 76455 7209 6699 204526 176890 17196 10440 PRINTING & PUBLICATIONS 4079253 4062223 0 17030 POSTAGE & SHIPPING 225027 71338 7274 146415 DUES & SUBSCRIPTIONS 127635 27355 660 99620 TELEPHONE 104240 90786 6212 7242 19604 16676 1762 1166 18411117 16397425 880033 1133659 1051106 525034 4723457 5256864 1689385 1206327 770854 730170 1195417 782159 119750 413258 9164634 9304632 88632 72187 855649 736951 18463467 18245423 1182502 2487370 4180718 4443378 1398209 796831 6761429 7727579 X 11365238 10308157 336800 209687 11702038 10517844 18463467 18245423 -1665431 481237 0 X X 0 1 X 1 0 X 19852188 14700757 17091762 17808047 16285176 85737930 19852188 14700757 17091762 17808047 16285176 85737930 37274350 48463580 371600 459595 650821 -1273744 918530 1126802 86864732 0.55790 0.55320 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 16641 186817 203458 17207659 17411117 1000000 250000 0 0 886122 914189 914189 1000000 3714500 5571750 256793 250438 215722 203458 926411 221531 228547 228547 250000 928625 1392938 90046 135269 37316 16641 279272 9390 861 8529 985619 590439 395180 200408 190859 9549 413258 ANNUITY PYMT LIABILITY 50619 LEASE LIABILITY 746212 796831 X 17226923 481237 481237 16745686 0 16745686 18411117 0 18411117 0 18411117 PART X, LINE 2: MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE ENTITY AND HAS CONCLUDED THAT AS OF SEPTEMBER 30, 2023, THERE WERE NO UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN. ACCORDINGLY, NO INTEREST OR PENALTIES RELATED TO UNCERTAIN TAX POSITIONS WERE ACCRUED IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE ENTITY IS SUBJECT TO AUDITS BY TAXING JURISDICTIONS, HOWEVER, NO AUDITS FOR ANY TAX PERIODS ARE CURRENTLY IN PROGRESS. MANAGEMENT BELIEVES THAT THE ENTITY IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS FOR YEARS ENDED ON OR PRIOR TO SEPTEMBER 30, 2020 UNDER FEDERAL AND CALIFORNIA TAX JURISDICTIONS. 1 EUROPE 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED RESEARCH PROJECTS, CONDUCTED RESEARCH CONFERENCE, AN AWARDS CEREMONY, PATIENT AND PHYSICIAN EDUCTION. 1814674 EAST ASIA AND THE PACIFIC 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED RESEARCH PROJECTS, CONDUCTED RESEARCH CONFERENCE, PATIENT AND PHYSICIAN EDUCATION. 872936 NORTH AMERICA - CANADA 0 0 PROGRAM SERVICES CONDUCTED RESEARCH PROJECTS, PATIENT EDUCATION. 297602 MIDDLE EAST - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICES CONDUCTED PATIENT & FAMILY SEMINARS. GRAPHIC DESIGN AND LAYOUT SERVICES. 108448 SOUTH AMERICA 0 0 PROGRAM SERVICES AWARDED GRANTS. 43000 2 2 0 0 2 2 3136660 0 3136660 EUROPE (INCLUDING ICELAND & GREENLAND) SUPPORTING EDUCATION AND OUTREACH TO LOCAL COMMUNITIES OF MYELOMA PATIENT ORGANIZATIONS. 8000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM DECIPHERING THE EPIGENOMIC MECHANISMS OF TRANSFORMATION FROM BENIGN MONOCLONAL GAMMOPATHIES TO SYMPTOMATIC MULTIPLE MYELOMA. 26667 0 SOUTH AMERICA SUPPORTING EDUCATION AND OUTREACH TO LOCAL COMMUNITIES OF MYELOMA PATIENT ORGANIZATIONS. 8000 0 SOUTH AMERICA HELPING IMPROVE THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 35000 0 EUROPE (INCLUDING ICELAND & GREENLAND) SUPPORTING EDUCATION AND OUTREACH TO LOCAL COMMUNITIES OF MYELOMA PATIENT ORGANIZATIONS. 8000 0 EAST ASIA AND THE PACIFIC SUPPORTING EDUCATION AND OUTREACH TO LOCAL COMMUNITIES OF MYELOMA PATIENT ORGANIZATIONS. 8000 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM DEFINING A NOVEL FUNCTION FOR THE POST TRANSLATIONAL MODIFICATION UFMYLATION IN THE ADAPTIVE RESPONSE TO ARGININE DEPRIVATION IN MULTIPLE MYELOMA. 33333 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM DISSECTING THE NUTRITIONAL INTERACTION BETWEEN MULTIPLE MYELOMA AND MESENCHYMAL STROMAL CELLS REVEALS NOVEL TARGETABLE PATHWAYS. 16667 0 0 0 0 0 0 0 PART I, LINE 2: FOR RESEARCH GRANT FUNDS, REPORTS ARE PROVIDED AS PART OF THE REQUIRED GRANT COMPLIANCE PROCESS BUILT INTO THE GRANT AGREEMENT. PART III ACCOUNTING METHOD: SALON 26475 19741 6734 6734 26475 19741 6734 6734 6734 0 N/A 1 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02115 042263040 IRC SEC 501(C)(3) 33333 0 DEFINING CELL STATES UNDERLYING TREATMENT RESISTANCE IN MYELOMA BY INTEGRATING MULTIOMIC SEQUENCING DATA UNIVERSITY OF SAN DIEGO 9500 GILMAN DR DEPT 0009 SAN DIEGO CA 92093 943067788 IRC SEC 501(C)(3) 16667 0 TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4 CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVE CLEVELAND OH 44106 341018992 IRC SEC 501(C)(3) 53333 0 NOVEL ADJUVANTS TO PROTEASOME INHIBITORS FOR MYELOMA THERAPY TRUSTEES OF BOSTON UNIVERSITY 1 SILBER WAY BOSTON MA 02115 042103547 IRC SEC 501(C)(3) 16667 0 DEFINING A MOLECULAR SIGNATURE OF CARDIOTOXICITY IN SYSTEMIC IMMUNOGLOBIN LIGHT CHAIN AMYLOIDOSIS PART I, LINE 2: USE OF GRANT FUNDS ARE MONITORED ACCORDING TO TERMS AND PROCEDURES DEFINED IN THE GRANT AGREEMENT. 1 X X X X 0 0 0 0 0 0 0 1 0 JOSEPH MIKHAEL CHIEF MEDICAL OFFICER 455869 0 0 0 0 0 0 0 0 16868 455869 16868 0 0 YELAK BIRU CEO, PRESIDENT 412083 0 0 0 0 0 0 0 0 17822 412083 17822 0 0 DIANE MORAN STRATEGIC PLANNER 409891 0 0 0 0 0 0 0 0 15369 409891 15369 0 0 DR BRIAN DURIE DIRECTOR 342333 0 0 0 0 0 0 0 0 358 342333 358 0 0 JENNIFER SCARNE CHIEF FINANCIAL OFFICER 263885 0 17500 0 0 0 0 0 0 20241 281385 20241 0 0 SUSAN DURIE DIRECTOR 256967 0 0 0 0 0 0 0 0 28716 256967 28716 0 0 LISA PAIK SENIOR VICE PRESIDENT 247083 0 10000 0 0 0 0 0 0 23854 257083 23854 0 0 PETER ANTON VICE PRESIDNENT, MARKETING 194913 0 10000 0 0 0 0 0 0 28760 204913 28760 0 0 LYNN GREEN SENIOR VICE PRESIDENT, PHI 220843 0 7500 0 0 0 0 0 0 570 228343 570 0 0 PART I, LINE 7 BONUSES PAID: JENNIFER SCARNE - $17,500 LISA PAIK - $10,000 PETER ANTON - $10,000 LYNN GREEN - $7,500 FORM 990, PART VI, SECTION A, LINE 2 SUSIE DURIE, FOUNDER AND DIRECTOR OF GLOBAL PATIENT INITIATIVES AND DR. BRIAN DURIE, CHAIRMAN OF THE BOARD AND CHIEF SCIENTIFIC OFFICER ARE HUSBAND AND WIFE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE OF THE BOARD FOR REVIEW PRIOR TO FILING THE TAX RETURN. FORM 990, PART VI, SECTION B, LINE 12C THIS PROCEDURE IS PERFORMED ANNUALLY AT THE ORGANIZATION'S BOARD OF DIRECTORS RETREAT. FORM 990, PART VI, SECTION B, LINE 15 FOR KEY EMPLOYEES, A REVIEW OF COMPARABLE COMPENSATION DATA IS REVIEWED BY THE FINANCE COMMITTEE. MEMBERS OF THE FINANCE COMMITTEE APPROVE OF THE COMPENSATION PACKAGE AND WOULD NOT HAVE A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT ISSUE. THE DECISION IS DISCUSSED AND RECORDED IN THE EXECUTIVE COMMITEE AND FINANCE COMMITTEE BOARD OF DIRECTOR MEETING MINUTES. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS OF THE ORGANIZATION ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE, AND UPON REQUEST. THESE DOCUMENTS HAVE BEEN PROVIDED TO A THIRD PARTY WEBSITE "CHARITY NAVIGATOR: YOUR GUIDE TO INTELLIGENT GIVING." PART XII, LINE 2C THE AUDIT OVERSIGHT COMMITTEE HAS NOT CHANGED ITS PROCESS SINCE THE PRIOR YEAR.